Table 1. Baseline characteristic.
| Variables | All patients (n=141) |
|---|---|
| Age, mean ± SD | 50.10±13.56 |
| Male, n (%) | 107 (0.76) |
| Clear cell carcinoma, n (%) | 103 (0.73) |
| KPS ≥80, n (%) | 105 (0.74) |
| Hypertension, n (%) | 36 (0.26) |
| Hypertension medication, n (%) | 20 (0.14) |
| Diabetes, n (%) | 10 (0.07) |
| Resection of primary lesion, n (%) | |
| Partial nephrectomy | 20 (0.14) |
| Radical nephrectomy | 91 (0.65) |
| IMDC classification, n (%) | |
| Favorable | 23 (0.16) |
| Intermediate | 70 (0.50) |
| Poor | 48 (0.34) |
| Tumor metastasis site, n (%) | |
| Bone | 51 (0.36) |
| Liver | 10 (0.07) |
| Lung | 63 (0.45) |
| Lymph node | 76 (0.54) |
| Colon | 6 (0.04) |
| Pancreas | 4 (0.03) |
| Types of TKI, n (%) | |
| Sunitinib | 74 (0.52) |
| Axitinib | 75 (0.53) |
| Pazopanib | 35 (0.25) |
| Sorafenib | 12 (0.08) |
| Duration of TKI, months, mean ± SD | 22.98±17.60 |
| The administration of PD-1inhibitor, n (%) | 66 (0.47) |
| Baseline renal function, median (IQR) | |
| eGFR, mL/min/1.73 m2 | 81.56 (36.74) |
| SCr, mmol/L | 90.35 (38.33) |
| BUN, mmol/L | 6.00 (2.87) |
| CYSC, mg/L | 1.08 (0.40) |
SD, standard deviation; KPS, Karnofsky performance status; IMDC, International Metastatic Renal-Cell Carcinoma; TKI, tyrosine kinase inhibitor; PD-1, programmed cell death protein 1; IQR, inter quartile range; eGFR, estimated glomerular filtration rate; SCr, serum creatinine; BUN, blood urea nitrogen; CYSC, cystatin C.